Pelaia, C.; Crimi, C.; Nolasco, S.; Carpagnano, G.E.; Brancaccio, R.; Buonamico, E.; Campisi, R.; Gagliani, C.; Patella, V.; Pelaia, G.;
et al. Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy. Biomedicines 2021, 9, 1822.
https://doi.org/10.3390/biomedicines9121822
AMA Style
Pelaia C, Crimi C, Nolasco S, Carpagnano GE, Brancaccio R, Buonamico E, Campisi R, Gagliani C, Patella V, Pelaia G,
et al. Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy. Biomedicines. 2021; 9(12):1822.
https://doi.org/10.3390/biomedicines9121822
Chicago/Turabian Style
Pelaia, Corrado, Claudia Crimi, Santi Nolasco, Giovanna Elisiana Carpagnano, Raffaele Brancaccio, Enrico Buonamico, Raffaele Campisi, Claudia Gagliani, Vincenzo Patella, Girolamo Pelaia,
and et al. 2021. "Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy" Biomedicines 9, no. 12: 1822.
https://doi.org/10.3390/biomedicines9121822
APA Style
Pelaia, C., Crimi, C., Nolasco, S., Carpagnano, G. E., Brancaccio, R., Buonamico, E., Campisi, R., Gagliani, C., Patella, V., Pelaia, G., Valenti, G., & Crimi, N.
(2021). Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy. Biomedicines, 9(12), 1822.
https://doi.org/10.3390/biomedicines9121822
